Infliximab and adalimumab ( DrugBank: Adalimumab, Infliximab )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
96	クローン病	2
97	潰瘍性大腸炎	2

96. クローン病

---

臨床試験数 : 2,400 /  薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2011-006084-22-GB (EUCTR)	04/10/2012	15/08/2012	Usefulness of the measurement of blood levels of infliximab and adalimumab in inflammatory bowel disease patients in predicting response to treatment	Utilising drug levels and anti-drug antibodies to predict response to treatment in patients with Inflammatory Bowel Disease - Trough levels of anti-TNF agents in inflammatory bowel disease	Inflammatory bowel disease MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 14.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Remicade Product Name: Infliximab INN or Proposed INN: Infliximab Trade Name: Humira Product Name: adalimumab INN or Proposed INN: Adalimumab	Royal Liverpool University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	0		United Kingdom
2	NCT02322008 (ClinicalTrials.gov)	September 2009	17/12/2014	Anti-TNF Therapy in Danish Patients With Inflammatory Bowel Diseases in Clinical Practice	Anti-TNF Therapy in Danish Patients With Inflammatory Bowel Diseases in Clinical Practice	Crohn's Disease;Ulcerative Colitis;Inflammatory Bowel Disease	Biological: infliximab and adalimumab	Regionshospitalet Viborg, Skive	NULL	Completed	18 Years	N/A	Both	1035	N/A	NULL

97. 潰瘍性大腸炎

---

臨床試験数 : 2,527 /  薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2011-006084-22-GB (EUCTR)	04/10/2012	15/08/2012	Usefulness of the measurement of blood levels of infliximab and adalimumab in inflammatory bowel disease patients in predicting response to treatment	Utilising drug levels and anti-drug antibodies to predict response to treatment in patients with Inflammatory Bowel Disease - Trough levels of anti-TNF agents in inflammatory bowel disease	Inflammatory bowel disease MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 14.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Remicade Product Name: Infliximab INN or Proposed INN: Infliximab Trade Name: Humira Product Name: adalimumab INN or Proposed INN: Adalimumab	Royal Liverpool University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	0		United Kingdom
2	NCT02322008 (ClinicalTrials.gov)	September 2009	17/12/2014	Anti-TNF Therapy in Danish Patients With Inflammatory Bowel Diseases in Clinical Practice	Anti-TNF Therapy in Danish Patients With Inflammatory Bowel Diseases in Clinical Practice	Crohn's Disease;Ulcerative Colitis;Inflammatory Bowel Disease	Biological: infliximab and adalimumab	Regionshospitalet Viborg, Skive	NULL	Completed	18 Years	N/A	Both	1035	N/A	NULL